

Cawangan Negeri Sembilan Kampus Kuala Pilah

ENT300

FUNDAMENTALS OF ENTREPRENEURSHIP BUSINESS PLAN SEMESTER OCTOBER 2024 – FEBRUARY 2025



GenVax Biopharma

NAME	STUDENT ID
ADEEBA SAFIA BINTI NOOR AZHARI	2023172719
KHAIRUN NUR NAJIHAH BINTI AMIR	2022838466
NOR SYAZWANNI BINTI ZAINUDIN	2023135659
SITI NURUL IZZANIE BINTI MOHD. SOLEH	2023135273
SITI NUR INSYIRAH BINTI ROBIAN	2023509323

GROUP	AS1164A1
DATE OF SUBMISSION	25 JANUARY 2025
PREPARED FOR	MS. NUR EZLEEN BATRISYAH ABD. AZIZ

TABLE OF CONTENTS

Contents	Page
1.0 Executive Summary	
2.0 Business Background	
2.1 Company Background	
2.2 Partner's Background	
2.3 Business Partnership	
3.0 Administration Plan	
3.1 About Us	
3.1.1 Vision	
3.1.2 Mission	
3.1.3 Objectives and Goals	
3.2 Organization Chart	
3.3 Administration Personnel Schedule	
3.4 Task and Responsibilities	
3.5 Remuneration Schedule	
3.6 Office Equipment and Suppliers	
3.7 Administration Budget	
4.0 Marketing Plan	
4.1 Product and Service Description	
4.2 Target Market	
4.3 Market Size and Sales Forecast	
4.3.1 Market Size	
4.3.2 Market Share Before Company has Started	
4.3.3 Market Share After Company has Started	
4.3.4 Sales Forecast of GenVax Biopharma for Year 2025	
4.3.5 Sales Forecast of GenVax Biopharma for Second and	
Third Year	
4.4 Marketing or Product Strategies	
4.4.1 Product Strategy	

4.4.2	Price Strategy
4.4.3	Place (Distribution Channels)
4.4.4	Promotion Strategy
4.5 Competito	ors Analysis and Market Share
4.5.1	Competitors
4.5.2	Market Share Before and After Entrance of GenVax
	Biopharma Competitors Percentage of Market
4.6 Marketing	Personnel Schedule
4.7 Remunera	tion Schedule
4.8 Marketing	Mix
4.9 List of Fur	rniture and Fitting
4.10 List of	Office Equipment
4.11 Marke	ting Budget
5.0 Operation Plan	
5.1 Process Pl	anning
5.1.1	Process Planning
5.1.2	Production Flow
5.2 Operation	Layout
5.3 Production	n / Capacity Planning
5.4 Material R	Requirement Planning
5.5 Machine a	and Equipment Planning
5.6 Locations	
5.7 Business a	and Operation Hours
5.8 Operation	Personnel Schedule
5.9 Remunera	tion Schedule
5.10 Permit	ss / Licenses Requirement
5.11 Operat	tional Budget
6.0 Financial Plan	
6.1 Operationa	al Budgets
6.2 Implement	tation Cost and Sources of Financing
6.3 Pro Forma	a Cash Flow (3 years)
	<u>l</u>

6.4 Pro Forma Income Statement (3 years)	
6.5 Pro Forma Balance Sheet (3 years)	
6.6 Financial Ratio Statistics	
7.0 Conclusion	
8.0 Appendices	

1.0 EXECUTIVE SUMMARY

GenVax Biopharma is a pioneering vaccine development company dedicated to improving global health through the research, development, and distribution of advanced vaccine solutions. As a world-leading company in the biopharmaceutical sector, GenVax Biopharma are committed to protecting communities around the world by tackling both emerging and existing infectious diseases. Utilizing the latest developments in biotechnology, GenVax Biopharma focuses on creating both mRNA-based vaccines and traditional vaccine technologies, serving to the varied health needs of populations worldwide. Our company sustain high standards of safety, efficacy, and accessibility in all our vaccine contribution, ensuring that our solutions reach those who need them the most.

At GenVax Biopharma, we emphasize scientific reliability and quality throughout every phase of vaccine development, from initial concept to clinical trials and production. Our strong research foundation and a team of highly skilled scientists and industry professionals certify us to rapidly address public health challenges. Our advanced production facilities are equipped with the latest technologies that comply with strict manufacturing standards, while our regulatory framework guarantees that all products meet global safety and quality requirements.

Beyond developing life-saving vaccines, GenVax Biopharma collaborates with governments, healthcare providers, and non-profit organizations to enhance global health infrastructure. By partnering with these shareholders, we strive to improve vaccine distribution networks, especially in underprivileged areas. Our mission reaches out beyond preventing and reducing the spread of infectious diseases, as we aim to contribute to a healthier, disease-free future for everyone. With our dedication to innovation, thorough research, and global collaboration, GenVax Biopharma is set to lead the future of vaccine science, making a significant impact on global health.

3.0 ADMINISTRATIVE PLAN

3.1 ABOUT US

GenVax Biopharma, a world-leading innovator in vaccine research, development and production, dedicated to advancing global health through scientifically advanced, high-quality vaccines. Founded on the principles of innovation, safety and efficacy, GenVax Biopharma utilize advanced biotechnology and precise clinical research to address the world's most pressing infectious diseases. With a commitment to public health and accessibility, we partner with healthcare organizations and communities worldwide to ensure our vaccines reach those who need them the most, creating a healthier future for all.

3.1.1 VISION

Here in GenVax, we stand on four main visions. Our primary vision is to revolutionize healthcare by pioneering in vaccine innovations, making a world a safer and healthier place. We foresee a world where vaccine technology not only protects but enhances quality of life, protecting people of all ages and generations from preventable diseases. Second, we aim to be recognized globally as a trusted leader in preventive healthcare and immunology, align with our reliability, safety and advanced research. Third, our main goal is we seek to drive a future where vaccine-preventable diseases are eradicated for people of all generations. Fourth, we work towards ensuring that life-saving vaccines are accessible to all, regardless of geographical or economic boundaries. These four visions emphasize our commitment to health fairness, ensuring that no one is left vulnerable to infectious diseases.

3.1.2 MISSION

Our mission at GenVax Biopharma is to develop vaccines that are safe, effective and accessible which address both existing and emerging infectious diseases. We are dedicated to creating vaccines that are capable to protect the world's most vulnerable populations, regardless of financial barriers, since we focus on affordability and access. As a science-driven company, we strive for sustainable